[go: up one dir, main page]

MX2016016118A - Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. - Google Patents

Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.

Info

Publication number
MX2016016118A
MX2016016118A MX2016016118A MX2016016118A MX2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A
Authority
MX
Mexico
Prior art keywords
disorders
methods
prophylaxis
treatment
diseases
Prior art date
Application number
MX2016016118A
Other languages
English (en)
Other versions
MX377588B (es
Inventor
CHEUNG Steve
Chin Boon Wah
Original Assignee
Univ Deakin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902173A external-priority patent/AU2014902173A0/en
Application filed by Univ Deakin filed Critical Univ Deakin
Publication of MX2016016118A publication Critical patent/MX2016016118A/es
Publication of MX377588B publication Critical patent/MX377588B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere en general a métodos para el tratamiento y/o profilaxis de enfermedades neurológicas y trastornos que involucran la administración de trans 10-HDA. En particular, los métodos de la presente invención son útiles en el tratamiento y/o profilaxis de trastornos y condiciones del neurodesarrollo adquiridos o progresivos en mamíferos. Más particularmente, se enseñan aquí métodos para el tratamiento y/o la profilaxis de enfermedades y trastornos tales como trastornos del espectro autista.
MX2016016118A 2014-06-06 2015-06-05 Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. MX377588B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014902173A AU2014902173A0 (en) 2014-06-06 Methods of treating neurodevelopmental diseases and disorders
PCT/AU2015/050310 WO2015184509A1 (en) 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders

Publications (2)

Publication Number Publication Date
MX2016016118A true MX2016016118A (es) 2017-07-26
MX377588B MX377588B (es) 2025-03-10

Family

ID=54765877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016118A MX377588B (es) 2014-06-06 2015-06-05 Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.

Country Status (12)

Country Link
US (3) US9925163B2 (es)
EP (1) EP3151824B1 (es)
JP (2) JP6598262B2 (es)
KR (1) KR102496390B1 (es)
CN (1) CN106659704B (es)
AU (3) AU2015271652B2 (es)
BR (1) BR112016028653A2 (es)
CA (1) CA2951288C (es)
ES (1) ES3014042T3 (es)
MX (1) MX377588B (es)
NZ (1) NZ727412A (es)
WO (1) WO2015184509A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151824B1 (en) 2014-06-06 2025-03-05 Meizon Innovation 2 Pty Ltd Trans-10-hydroxy-2-decenoic acid for use in the treatment of autism spectrum disorder
ES2952610T3 (es) * 2015-12-04 2023-11-02 Wah Chin Boon Métodos para tratar o aliviar trastornos mentales y síntomas asociados
CN116570582A (zh) * 2023-05-19 2023-08-11 中国药科大学 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025185A (en) 1911-03-23 1912-05-07 William J Gruss Regrinder.
JPH0967252A (ja) 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
WO2007130581A2 (en) 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
JP5447954B2 (ja) 2007-09-19 2014-03-19 公益財団法人名古屋産業科学研究所 神経栄養因子様作用剤
CN101801398A (zh) 2008-06-17 2010-08-11 日本蜂王浆株式会社 认知障碍改善剂
LT2667715T (lt) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
US10052319B2 (en) * 2012-04-26 2018-08-21 Sumitomo Dainippon Pharma Co., Ltd. Medicament for treating mental and behavioural disorders
EP2842942B1 (en) * 2012-04-27 2016-12-07 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
CN103816307B (zh) 2014-03-12 2016-09-14 张国显 神经生长再造丸及其制备方法
EP3151824B1 (en) 2014-06-06 2025-03-05 Meizon Innovation 2 Pty Ltd Trans-10-hydroxy-2-decenoic acid for use in the treatment of autism spectrum disorder
ES2952610T3 (es) 2015-12-04 2023-11-02 Wah Chin Boon Métodos para tratar o aliviar trastornos mentales y síntomas asociados

Also Published As

Publication number Publication date
US20170087110A1 (en) 2017-03-30
CN106659704B (zh) 2020-03-10
KR102496390B1 (ko) 2023-02-03
US10933043B2 (en) 2021-03-02
AU2025200041A1 (en) 2025-01-23
NZ727412A (en) 2023-07-28
US10251856B2 (en) 2019-04-09
ES3014042T3 (en) 2025-04-16
AU2021221914A1 (en) 2021-09-23
CA2951288A1 (en) 2015-12-10
CA2951288C (en) 2024-01-02
BR112016028653A2 (pt) 2018-07-10
CN106659704A (zh) 2017-05-10
WO2015184509A1 (en) 2015-12-10
US9925163B2 (en) 2018-03-27
JP6994613B2 (ja) 2022-01-14
EP3151824B1 (en) 2025-03-05
AU2015271652A1 (en) 2017-01-05
US20180214405A1 (en) 2018-08-02
AU2015271652B2 (en) 2021-05-27
JP2017517574A (ja) 2017-06-29
JP2019214623A (ja) 2019-12-19
EP3151824A4 (en) 2017-12-20
EP3151824A1 (en) 2017-04-12
EP3151824C0 (en) 2025-03-05
MX377588B (es) 2025-03-10
US20190314315A1 (en) 2019-10-17
JP6598262B2 (ja) 2019-10-30
KR20170026457A (ko) 2017-03-08

Similar Documents

Publication Publication Date Title
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX2017012699A (es) Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
PT3297644T (pt) Métodos para tratar distúrbios do espetro do autismo e sintomas associados
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
MX2015011434A (es) Partículas inmunomodificadoras para el tratamiento de la inflamación.
DOP2017000139A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
CL2020000085A1 (es) Moduladores de nlrp3.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2017008063A (es) Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5-tr imetil-3,6-dioxociclohexa-1,4-dienil)butanamida.
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
CR20170069A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.

Legal Events

Date Code Title Description
FG Grant or registration